Melanotan II vs Afamelanotide (Scenesse): Mechanism and Regulatory Reality

Few peptide names get blurred together as often as the melanotans. Online shops talk about "Melanotan I" and "Melanotan II" as if they were two strengths of the same tanning product, and they sometimes invoke the prescription drug afamelanotide to imply that the whole family is medically endorsed. That framing is misleading. One member of this family is an approved medicine for a rare disease; another is an unapproved compound sold informally for cosmetic tanning.

This article separates the three molecules people most often confuse: afamelanotide (sometimes labeled Melanotan I), Melanotan II, and bremelanotide. The goal is mechanism literacy, not endorsement. Understanding why these compounds differ at the receptor level explains why one earned a regulated label and the others did not.

For baseline context on the molecule at the center of the marketing, start with the Melanotan II peptide guide and the companion article on Melanotan II side effects and safety.

Why The Distinction Matters

When a seller borrows the name or reputation of an approved drug to market an unapproved one, that is a classic evidence-transfer error. A regulatory approval is tied to a specific molecule, a specific dose form, a specific indication, and a specific patient population. It does not spread to a chemically related compound just because the names sound similar or the receptors overlap.

The melanotan family is a textbook example. Afamelanotide is approved, supervised, and dose-controlled. Melanotan II is none of those things in consumer channels. Treating them as interchangeable is the central mistake this page is built to prevent.

The Melanocortin System In Plain Terms

All three compounds are analogs of alpha-melanocyte-stimulating hormone (alpha-MSH), a natural signaling peptide. They act on melanocortin receptors, a family numbered MC1 through MC5. Each receptor subtype does different work: MC1 is central to skin pigmentation, while MC3 and MC4 are involved in appetite, energy balance, and sexual response, and MC5 has other roles.

That receptor map is the key to everything that follows. A compound that hits mostly MC1 will tend to act on pigmentation. A compound that spreads its activity across MC1, MC3, MC4, and MC5 will reach pathways far beyond the skin. The breadth of receptor binding, not the marketing label, predicts how "systemic" a melanotan analog behaves.

Side-By-Side: Three Molecules People Confuse

Afamelanotide (Scenesse): The Approved Member

Afamelanotide is a linear tridecapeptide, a 13-amino-acid analog of alpha-MSH that binds predominantly to the MC1 receptor. By stimulating MC1, it increases production of eumelanin in the epidermis independent of sunlight. The approved use is narrow and specific: it is for adults with erythropoietic protoporphyria (EPP), a rare inherited disorder in which protoporphyrin IX accumulates and reacts with light to cause intense skin pain.

The clinical record behind that approval is real. Two randomized, double-blind, placebo-controlled trials in the European Union and the United States tested a 16 mg controlled-release subcutaneous implant given roughly every two months. Patients reported more pain-free time in sunlight than those on placebo. The European Medicines Agency authorized Scenesse in 2014, and the FDA approved it in October 2019 as the first treatment to increase pain-free light exposure in EPP.

Crucially, afamelanotide is prescribed by specialist physicians in recognized centers and delivered as a dose-controlled implant, not a self-injected tan. Its approval is a statement about EPP, not a green light for cosmetic pigmentation in healthy people.

Melanotan II: The Unapproved Cousin

Melanotan II is structurally different. It is a cyclic, more compact 7-amino-acid analog, and instead of concentrating on MC1, it binds across MC1, MC3, MC4, and MC5. That broader reach is exactly why it is associated with effects beyond tanning, including appetite changes, nausea, flushing, and erection or libido effects reported in early human work such as a 1996 pilot phase I study and later melanocortin research on sexual response.

None of that broad activity has produced an approved tanning product. Melanotan II circulates as a research-market powder, vial, or nasal spray. A Drug Testing and Analysis study that chemically analyzed melanotan products sold online underscores the problem: consumers are rarely dealing with a labeled, quality-controlled medicine, so identity, purity, concentration, and sterility can be hard to verify. Case reports of serious events, including systemic toxicity with rhabdomyolysis, add further caution.

In short, Melanotan II shares a receptor family with afamelanotide but not its evidence base, its quality control, or its supervised dosing. The broader receptor profile is a reason for more caution, not less.

The Regulatory Reality

Regulators have drawn this line repeatedly. Australia's Therapeutic Goods Administration warns against tanning products containing melanotan and notes that melanotan pigmentation does not protect skin the way suitable sunscreen does. Ireland's Health Products Regulatory Authority has issued reminders about serious health risks from Melanotan 2 self-tan products. These notices target the unapproved tanning use specifically.

Meanwhile, the approved product, Scenesse, sits in a completely different regulatory category: a rare-disease medicine with a defined label, supervised administration, and a documented trial program reflected in the FDA's drug-trials materials and the EMA assessment report. The contrast is the whole point. An approval in one corner of the melanocortin family says nothing about the safety or legality of an unapproved product in another corner.

Why The Names Blur Together

The confusion is partly historical and partly commercial. "Melanotan" was an early research codename, and the numbering ("Melanotan I" and "Melanotan II") makes the two molecules sound like sequential versions of one product. Sellers benefit from that ambiguity, because associating an unapproved tan with an approved drug lends borrowed credibility.

It helps to anchor on three facts. First, afamelanotide and Melanotan II are chemically distinct, with different receptor profiles. Second, only afamelanotide carries an approval, and only for a rare disease under specialist care. Third, bremelanotide (PT-141), a Melanotan II metabolite, is approved for an entirely different indication, which is why it should not be folded into tanning discussions either. For more on that molecule, see the PT-141 and bremelanotide guide.

Reader Checklist

Before trusting any melanotan claim, separate the molecule from the marketing:

• Which exact compound is being discussed: afamelanotide, Melanotan II, or bremelanotide?
• Is an approval being cited for the same molecule, dose form, and indication, or borrowed from a cousin?
• Does the source acknowledge that afamelanotide is approved only for erythropoietic protoporphyria under specialist care?
• Does it treat Melanotan II's broad receptor activity as a safety concern rather than a feature?
• Does it avoid blending tanning, libido, and disease-treatment claims into one pitch?
• Is the source selling a product, or providing primary evidence and regulator context?

Keep the takeaway restrained. The melanotan family holds one approved rare-disease medicine and one unapproved tanning compound: overlapping biology, very different evidence and oversight. Shared receptors do not mean shared safety.

FAQ

Is afamelanotide the same as Melanotan II?

No. Afamelanotide (sometimes called Melanotan I) is a different molecule with a different receptor profile, and it is an approved prescription implant for a rare disease. Melanotan II is an unapproved, broadly acting analog sold informally.

Does an approved cousin make Melanotan II safe to use for tanning?

No. Afamelanotide approval applies only to a tightly defined disease, dose, and supervised implant. It does not transfer evidence, quality control, or safety assurance to Melanotan II products bought online.

Is Scenesse approved as a cosmetic tan?

No. Scenesse is approved to increase pain-free light exposure in adults with erythropoietic protoporphyria, prescribed in specialist centers. It is not a cosmetic tanning product.

References

• SCENESSE (afamelanotide) approval record (BLA 210797), Drugs@FDA, U.S. Food and Drug Administration.
• SCENESSE (afamelanotide) FDA prescribing information (2019), U.S. Food and Drug Administration.
• Scenesse (afamelanotide): European public assessment report, European Medicines Agency.
• Afamelanotide for Erythropoietic Protoporphyria, New England Journal of Medicine / PubMed.
• Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study, Life Sciences / PubMed.
• Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II, International Journal of Impotence Research / PubMed.
• Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet, Drug Testing and Analysis / PubMed.
• Melanotan II injection resulting in systemic toxicity and rhabdomyolysis, Clinical Toxicology / PubMed.
• Don't risk using tanning products containing melanotan, Therapeutic Goods Administration.
• Reminder of serious health risks with Melanotan 2 self-tan products, Health Products Regulatory Authority.

Disclaimer

This page is educational and is not medical advice. It does not provide dosing, reconstitution, injection, nasal-spray, sourcing, purchase, or treatment instructions for Melanotan II or afamelanotide. Melanotan II is not an FDA-approved tanning product, and afamelanotide (Scenesse) is a prescription medicine approved only for a specific rare disease under specialist supervision. Speak with a qualified healthcare professional about personal medical decisions, skin changes, medication use, and adverse symptoms.